Search | Clinical Trials Finder

Conditions: Overweight, Obesity
Interventions: Semaglutide, Placebo (Semaglutide); Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: Not listed
Enrollment: 304 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 15
States / cities: Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 12 more

Conditions: Diabetes, Diabetes Mellitus, Type 2
Interventions: insulin degludec/insulin aspart, insulin glargine; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 530 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 41
States / cities: Birmingham, Alabama • Vestavia Hills, Alabama • Concord, California + 33 more

Conditions: Diabetes, Gestational Diabetes
Interventions: human insulin, insulin NPH, insulin aspart; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2000 – 2003
U.S. locations: 1
States / cities: Santa Barbara, California

Conditions: Metabolism and Nutrition Disorder, Obesity
Interventions: Liraglutide, Placebo; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 12 Years to 17 Years
Enrollment: 251 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 13
States / cities: Meridian, Idaho • Baton Rouge, Louisiana • Baltimore, Maryland + 9 more

Conditions: NAFLD
Interventions: Semaglutide Pen Injector, Placebo; Drug
Lead sponsor: University of Virginia; Other
Eligibility: 18 Years to 75 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Diabetes, Diabetes Mellitus, Type 2
Interventions: liraglutide, glimepiride, placebo; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 746 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 102
States / cities: Concord, California • Escondido, California • Fullerton, California + 83 more

Conditions: Diabetes Mellitus, Type 2, Diabetic Peripheral Neuropathy
Interventions: CagriSema (Cagrilintide B and Semaglutide I), Placebo matched to CagriSema (Cagrilintide B and Semaglutide I); Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 142 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 20
States / cities: La Mesa, California • San Diego, California • Miami, Florida + 14 more

Conditions: Diabetes, Diabetes Mellitus, Type 1
Interventions: insulin degludec/insulin aspart, insulin detemir, insulin aspart; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 548 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 30
States / cities: La Mesa, California • Lancaster, California • Mission Hills, California + 25 more

Conditions: Diabetes, Diabetes Mellitus, Type 2
Interventions: insulin degludec/liraglutide, liraglutide, exenatide; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 438 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 85
States / cities: Birmingham, Alabama • Goodyear, Arizona • Mesa, Arizona + 73 more

Conditions: Diabetes, Diabetes Mellitus, Type 2
Interventions: semaglutide, placebo; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 50 Years and older
Enrollment: 3,183 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 71
States / cities: Little Rock, Arkansas • Searcy, Arkansas • Concord, California + 58 more

Conditions: Other Haemostasis Disorder, Haemorrhagic Cystitis
Interventions: activated recombinant human factor VII; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 2 Years to 65 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2003
U.S. locations: 3
States / cities: Chapel Hill, North Carolina • Houston, Texas

Conditions: Type 2 Diabetes Treated With Insulin
Interventions: Insulin glargine, NovoLog, Insulin Fiasp, Standard carbohydrate diet; Drug · Other
Lead sponsor: Boston Medical Center; Other
Eligibility: 21 Years to 80 Years
Enrollment: 137 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Inflammation, Systemic Lupus Erythematosus
Interventions: NNC 0151-0000-0000, placebo; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 1
States / cities: Lake Success, New York

Conditions: Transthyretin Amyloid Cardiomyopathy (ATTR CM)
Interventions: NNC6019-0001, Placebo (NNC6019-0001); Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 9
States / cities: Phoenix, Arizona • Beverly Hills, California • Stanford, California + 5 more

Conditions: Diabetes Mellitus, Type 1
Interventions: Insulin icodec, Insulin glargine, Insulin aspart; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 877 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 103
States / cities: Cullman, Alabama • Concord, California • Escondido, California + 85 more

Conditions: Metabolism and Nutrition Disorder, Obesity
Interventions: semaglutide, liraglutide, placebo; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 957 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 22
States / cities: Anaheim, California • San Diego, California • Golden, Colorado + 18 more

Conditions: Obesity, Overweight, Diabetes Mellitus, Type 2
Interventions: NNC0487-0111, Semaglutide, Placebo (matched to NNC0487-0111), Placebo (matched to semaglutide); Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 10
States / cities: Hollywood, Florida • Orange City, Florida • Weston, Florida + 7 more

Conditions: Type 2 Diabetes (T2D)
Interventions: NNC0487-0111 subcutanous, Placebo (NNC0487-0111 subcutanous), NNC0487-0111 oral, Placebo (NNC0487-0111 oral); Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 448 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 39
States / cities: Birmingham, Alabama • Los Angeles, California • Santa Ana, California + 30 more

Conditions: Diabetes Mellitus, Type 2
Interventions: Semaglutide, Placebo (semaglutide); Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 1,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 72
States / cities: Phoenix, Arizona • Tucson, Arizona • Coronado, California + 54 more

Conditions: Diabetes, Obesity
Interventions: Detemir; Drug
Lead sponsor: Vanderbilt University; Other
Eligibility: 31 Years to 60 Years
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2028
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Diabetes Mellitus, Type 2
Interventions: Insulin icodec, Insulin glargine, Insulin aspart; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: Not listed
Enrollment: 582 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 52
States / cities: Little Rock, Arkansas • Anaheim, California • Concord, California + 44 more

Conditions: Obesity
Interventions: NNC0487-0111, Placebo (matched to NNC0487-0111); Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 1,150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 22
States / cities: Miramar, Florida • Orlando, Florida • Conyers, Georgia + 19 more

Conditions: Bioequivalence
Interventions: KBP-5074 Capsule, KBP-5074 Tablet; Drug
Lead sponsor: KBP Biosciences; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Diabetes Mellitus, Type 2
Interventions: IcoSema, Insulin glargine, insulin aspart; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 679 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 66
States / cities: Guntersville, Alabama • Fresno, California • La Jolla, California + 59 more

Search by objective public record fields.

Two-year Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity

Comparison of NN5401 Versus Insulin Glargine, Both Combined With Metformin Treatment, in Subjects With Type 2 Diabetes

Safety and Efficacy of Insulin Aspart vs. Regular Human Insulin in Gestational Diabetes

Effect of Liraglutide for Weight Management in Pubertal Adolescent Subjects With Obesity

Randomized Double Blinded Placebo-Controlled w/Semaglutide to Prevent Weight Gain After Liver Transplant

To Evaluate the Effect of Liraglutide Versus Glimepiride (Amaryl®) on Haemoglobin A1c

A Research Study to Investigate the Effects of CagriSema Compared to Placebo in People With Type 2 Diabetes and Painful Diabetic Peripheral Neuropathy

Comparison of NN5401 Plus Insulin Aspart With Insulin Detemir Plus Insulin Aspart in Type 1 Diabetes

The Efficacy of Insulin Degludec/Liraglutide in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on GLP-1 Receptor Agonist and OAD Therapy

A Trial Investigating the Cardiovascular Safety of Oral Semaglutide in Subjects With Type 2 Diabetes

Efficacy and Safety of Activated Recombinant Human Factor VII in Refractory Haemorrhagic Cystitis

Novolog vs. Fiasp Insulin in Non-critically Ill Hospitalized Patients With Type 2 Diabetes Mellitus

An Investigation of NNC 0151-0000-0000 in Subjects With Systemic Lupus Erythematosus (SLE)

A Research Study to Look at How a New Medicine Called NNC6019-0001 Works and How Safe it is for People Who Have Heart Disease Due to Transthyretin (TTR) Amyloidosis

A Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine, Both in Combination With Insulin Aspart, in Adults With Type 1 Diabetes

Investigation of Safety and Efficacy of Once-daily Semaglutide in Obese Subjects Without Diabetes Mellitus

AMAZE 8: A Research Study Investigating How Well the Medicine NNC0487-0111 Compared to Semaglutide Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight

A Research Study Comparing How Well Different Doses of the Medicine NNC0487-0111 Lower Blood Sugar in People With Type 2 Diabetes

A Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes

Insulin Detemir in Obesity Management

A Research Study to Compare Two Types of Insulin, a New Weekly Insulin, Insulin Icodec and an Available Daily Insulin, Insulin Glargine, Both in Combination With Mealtime Insulin, in People With Type 2 Diabetes Who Use Daily Insulin and Mealtime Insulin (ONWARDS 4)

AMAZE 1: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Lose Weight

Bioavailability of KBP-5074 Tablet vs Capsule Formulations

A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Insulin Glargine Taken Daily With Insulin Aspart (COMBINE 3)